Bionano Genomics (BNGO)
NASDAQ:BNGO
Want to see BNGO full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.69Last Year’s EPS
-2Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized multiple positive operational and commercial developments: record Q1 flow cell unit sales, strong consumables growth, improved adjusted gross margin (49% vs 46% YoY), meaningful reimbursement wins that materially improve test economics, growing publication and clinical validation momentum, and balance sheet simplification through planned debt retirement. Offsetting these positives are continued revenue lumpiness (notably a 40% decline in software revenue due to a prior large sale), ongoing supply constraints that are improving, increased operating expenses ($9.1M vs $8.5M YoY) and a cash runway into 2027 with management not expecting cash flow breakeven in 2026. Overall, the call portrays improving commercialization traction and margin progress with material near-term financial and execution risks that management is addressing.Company Guidance
Revenue Growth and Guidance Reaffirmed
Q1 2026 revenue was $6.7 million, up 4% year-over-year and at the high end of guidance ($6.5M–$6.7M). Company reaffirmed full-year 2026 revenue guidance of $30M–$33M (growth of 5%–16% over 2025) and initiated Q2 2026 guidance of $7.5M–$7.8M (up 12%–16% vs Q2 2025).
Record Flow Cell Unit Sales and Utilization
Sold 8,178 nanochannel array flow cells in Q1 2026, a 17% year-over-year increase and the largest Q1 unit volume on record. Excluding flow cells tied to new systems, sales to existing customers were up 21% year-over-year, indicating stronger routine utilization.
Consumables and Recurring Revenue Momentum
Consumables revenue rose to $3.9 million in Q1, up 20% year-over-year. Other revenue was $1.6 million, up 36% year-over-year, pointing to a shift toward a higher proportion of recurring, more predictable revenue.
Improving Gross Margin and Operational Efficiency
Adjusted gross margin reached 49% in Q1 2026 versus 46% in Q1 2025, reflecting continued operational efficiencies and favorable revenue mix toward higher-margin consumables and software.
Meaningful Reimbursement Milestones
Two reimbursement milestones effective Q1 2026: Category 1 CPT payment for OGM in hematologic malignancies increased ~47% to $1,853.22 (from $1,263.53), and a separate Category 1 CPT for OGM in constitutional disorders has a payment determination of $1,263.53. Management highlighted these as material improvements to reimbursement economics and adoption barriers.
Scientific and Clinical Momentum
Substantial publication activity in Q1 2026: 28 OGM publications on rare diseases (≈56% increase YoY), 78 samples analyzed in those studies (≈225% increase YoY), and 1,991 genomes published in Q1 (≈158% increase YoY). Major studies (e.g., Johns Hopkins/MD Anderson) showed OGM outperforming traditional methods in multiple myeloma and recommended inclusion in workflows.
Events and Community Engagement Driving Visibility
Bionano Symposium 2026 attracted >1,250 registrants from 73 countries and showcased scale use cases (e.g., plans for 3,000 samples/year and Stratus processing 10,000 cancer samples/year), reinforcing movement from early adoption to scale.
Balance Sheet Simplification
Ended Q1 with $24.7 million in cash, cash equivalents, and available-for-sale securities (including $10.3M restricted). Company expects to fully retire outstanding senior secured convertible debt in May 2026, simplifying the financial profile.
BNGO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BNGO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $1.25 | $1.19 | -4.80% |
Mar 23, 2026 | $1.46 | $1.18 | -19.18% |
Nov 13, 2025 | $1.47 | $1.52 | +3.40% |
Aug 14, 2025 | $3.21 | $3.04 | -5.30% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Bionano Genomics (BNGO) report earnings?
Bionano Genomics (BNGO) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is Bionano Genomics (BNGO) earnings time?
Bionano Genomics (BNGO) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BNGO EPS forecast?
BNGO EPS forecast for the fiscal quarter 2026 (Q2) is -0.69.